Table 2 Morphological changes in LN in different anatomical regions of the pelvis
Total 5173 LN | OR | IER | IIR | EBR | OL | IEL | IIL | EBL |
|---|---|---|---|---|---|---|---|---|
919 (17.8%) | 667 (12.9%) | 677 (13.1%) | 318 (6.2%) | 882 (17.1%) | 724 (14.0%) | 714 (13.8%) | 272 (5.2%) | |
LN size | ||||||||
< 10 mm | 481 (17.8%) | 338 (12.5%) | 363 (13.4%) | 191 (7.0%) | 464 (17.2%) | 386 (14.3%) | 351 (13.0%) | 127 (4.8%) |
≥ 10 mm | 438 (17.7%) | 329 (13.3%) | 314 (12.7%) | 127 (5.1%) | 418 (16.9%) | 338 (13.7%) | 363 (14.7%) | 145 (5.9%) |
p = 0.012 | ||||||||
Lipomatous atrophy (%) | ||||||||
≤ 30 | 607 (17.5%) | 427 (12.3%) | 486 (14.0%) | 242 (7.0%) | 570 (16.5%) | 483 (13.9%) | 464 (13.4%) | 185 (5.4%) |
31–60 | 128 (18.9%) | 87 (12.8%) | 85 (12.5%) | 26 (3.8%) | 123 (18.1%) | 100 (14.7%) | 99 (14.6%) | 30 (4.4%) |
≥ 61 | 184 (17.8%) | 153 (14.8%) | 106 (10.3%) | 50 (5.0%) | 189 (18.3%) | 141 (13.7%) | 151 (14.6%) | 57 (5.7%) |
p = 0.011 | ||||||||
Framework fibrosis | ||||||||
Non | 637 (17.6%) | 473 (13.1%) | 460 (12.7%) | 229 (6.4%) | 624 (17.3%) | 528 (14.6%) | 487 (13.4%) | 176 (4.9%) |
Low | 224 (18.3%) | 157 (12.8%) | 171 (14.0%) | 74 (6.1%) | 194 (15.8%) | 145 (11.8%) | 182 (14.9%) | 77 (6.3%) |
Moderate | 54 (17.5%) | 34 (11.0%) | 41 (13.3%) | 15 (4.8%) | 57 (18.5%) | 48 (15.6%) | 40 (13.2%) | 19 (6.1%) |
High | 4 (14.8%) | 3 (11.1%) | 5 (18.5%) | 0 (0%) | 7 (25.9%) | 3 (11.1%) | 5 (18.6%) | 0 (0%) |
p = 0.005 | ||||||||
Capsular fibrosis | ||||||||
With | 289 (15.9%) | 243(13.4%) | 264 (14.6%) | 111 (6.1%) | 301 (16.6%) | 254 (14.0%) | 270 (14.9%) | 207 (6.2%) |
Without | 630 (18.8%) | 424 (12.6%) | 413 (12.3%) | 82 (4.5%) | 581 (17.3%) | 470 (14.0%) | 444 (13.2%) | 190 (5.6%) |
p = 0.060 | ||||||||
Calcifications | ||||||||
With | 426 (17.9%) | 298 (12.5%) | 315 (13.3%) | 129 (5.4%) | 411 (17.3%) | 335 (14.1%) | 334 (14.1%) | 128 (5.4%) |
Without | 493 (17.6%) | 369 (13.2%) | 362 (12.9%) | 189 (6.7%) | 471 (16.8%) | 389 (13.9%) | 380 (13.6%) | 144 (5.3%) |
p = 0.032 | ||||||||